However, carriers showed higher rates of family and personal history of breast and ovarian cancer, as well as a higher phenotype‐based risk score for BRCA1/2 mutations (DrABC score)[10] compared to non‐carriers (all P<0.05; Figure S2, Supporting Information). The gene discussed is BRCA1; the disease is ovarian cancer.